Authors: Jinlin Liu Zhao Zhao Yuqiong Zou Mei Zhang Yonglie Zhou Yasong Li Zhenzhen Pang Weidong Jin
Publish Date: 2015/01/08
Volume: 34, Issue: 5, Pages: 879-885
Abstract
Previous studies suggested a pathological role for the death decoy receptor 3 DcR3 in systemic lupus erythematosus SLE and rheumatic arthritis RA Herein the expression of DcR3 in primary Sjögren’s syndrome pSS and the relationship with clinical characteristics were investigated The serum DcR3 levels of pSS patients and healthy controls were measured by ELISA Pearson’s correlation analysis was used to evaluate the relationship between the DcR3 levels with the clinical characterstics of pSS patients Additionally the DcR3 expression in salivary glands of pSS patients was investigated by the immunohistochemistry method The serum DcR3 expression in pSS patients was significantly higher than healthy controls p 0001 especially in new onset pSS patients p = 0036 Moreover Pearson’s correlation analysis show that DcR3 levels were positively correlated with age p = 0013 platelet PLT p = 0002 hemoglobin Hb p = 0004 Sjögren’s syndrome disease damage activity index SSDAI score p = 0005 Sjögren’s syndrome disease damage index SSDDI score p 0001 and EULAR Sjögren’s syndrome disease activity index ESSDAI score p = 0010 Furthermore the DcR3 levels were significantly lower when the pSS patients were treated with the diseasemodifying antirheumatic drugs At last DcR3 expression in salivary glands of pSS patients was significantly higher than healthy controls The DcR3 expression was significantly elevated in the pSS patients and positively correlated with the clinical characteristics and it might be an important factor involved in the progression of pSS patients and could be a potential therapeutic target
Keywords: